Physician profile
Sharon N Hong
NPI 1275820722
$21,990.29
in general payments reported to CMS, 2019-2025
34 companies · $2,945 in 2025
The $2,945 reported for 2025 was more than what 77% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,087 · 2020: $3,009 · 2021: $2,736 · 2022: $2,778 · 2023: $3,370 · 2024: $3,065 · 2025: $2,945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,289 · Education: $90.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,289.48 |
| Education | $90.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,540.36 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Abbvie INC. | $4,448.85 | 2019-2025 | |
| Ucb, INC. | $2,131.75 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $1,825.39 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Novartis Pharmaceuticals Corporation | $1,182.41 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,175.38 | 2019-2025 | Benlysta |
| Pfizer INC. | $928.25 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $839.15 | 2019-2025 | Orencia |
| Genentech USA, INC. | $804.73 | 2019-2025 | Actemra |
| Lilly USA, LLC | $604.02 | 2019-2025 | Taltz, Zepbound, Olumiant |
| Astrazeneca Pharmaceuticals Lp | $559.85 | 2021-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $517.53 | 2019-2025 | Ofev, Cyltezo |
| Mallinckrodt Hospital Products INC. | $510.42 | 2020-2025 | Acthar |
| Radius Health, INC. | $418.02 | 2019-2024 | Tymlos |
| Regeneron Healthcare Solutions, INC. | $222.41 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $196.40 | 2022-2024 | |
| Genzyme Corporation | $128.60 | 2020-2021 | |
| Mallinckrodt Enterprises LLC | $123.70 | 2019 | |
| Aurinia Pharma U.S., INC. | $106.72 | 2022 | |
| Alexion Pharmaceuticals, INC. | $105.38 | 2020-2024 | Strensiq |
| Ani Pharmaceuticals, INC. | $89.94 | 2022-2025 | Purified Cortrophin Gel |
| Teva Pharmaceuticals USA, INC. | $83.04 | 2023-2024 | Truxima |
| Horizon Therapeutics Plc | $80.76 | 2021-2023 | Krystexxa |
| Fresenius Kabi USA, LLC | $79.08 | 2023-2025 | Idacio |
| Celgene Corporation | $52.88 | 2019 | |
| Invivyd INC | $40.15 | 2025 | Pemgarda |
| Actelion Pharmaceuticals US, INC. | $37.50 | 2022-2023 | Opsumit, Uptravi |
| Sandoz INC. | $34.74 | 2023-2024 | Hyrimoz |
| Ferring Pharmaceuticals INC. | $27.93 | 2024 | Euflexxa |
| Merck Sharp & Dohme LLC | $27.29 | 2019 | |
| Celltrion USA INC. | $20.41 | 2023 | Yuflyma |
| Fidia Pharma USA INC. | $20.28 | 2019 | |
| Tersera Therapeutics LLC | $16.35 | 2023 | Quzyttir |
| Janssen Scientific Affairs, LLC | $10.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Hong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.